Toll Free 1-877-266-8388 Tel: 1-408-747-0771
Fax: 1-408-470-7719
Quick Lead Time | Global Overnight Delivery Available
Purchase Order: info@signosisinc.com
Isoform-Specific NHR
Reporter Stable Cell Lines
While Nuclear Hormone Receptors (NHR) have distinct biological functions, their highly conserved DNA-binding domains and similar consensus response elements often make it difficult to distinguish between NHR isoforms using traditional assays. Signosis's Isoform-Specific NHR Reporter Stable Cell Lines overcomes this limitations by using the ligand-dependent GAL4 system, a powerful alternative to traditional DNA-binding assays.
These stable cell lines leverage the GAL4 two-hybrid system by fusing the ligand-binding domain (LBD) of a specific NHR isoforms to the GAL4 DNA-binding domain. This design enables isoform-specific detection of receptor activation based on functional response, rather than shared DNA-binding properties. By focusing on the LBD, these stable cell lines allow for precise, discriminative analysis of nuclear receptor activity—making them ideal for mechanistic studies, ligand screening, and drug discovery targeting pathways like PPARα, PPARγ, GRα, and more.
Principle
The NHR Reporter Stable Cell Lines are based on a GAL4-driven two-vector luciferase system designed for isoform-specific detection of nuclear hormone receptor activation. One vector expresses a chimeric protein combining the GAL4 DNA-binding domain (DBD) with the ligand-binding domain (LBD) of a specific NHR isoform. The second vector carries a luciferase reporter gene under the control of eight upstream activation sequences (UAS) recognized by GAL4.
Upon ligand binding, the DBD-LBD fusion protein undergoes conformational changes, enabling transcriptional activation of the luciferase reporter. This setup provides high sensitivity with low background signal and minimal cross-reactivity, as activation is strictly dependent on ligand interaction with the specific LBD. Stable cell lines were generated through dual antibiotic selection (hygromycin and neomycin) and validated for robust, ligand-induced luciferase expression, making them well-suited for screening and profiling NHR modulators.
Nuclear Hormone Receptor
Stable Cell Lines Products
GAL4-UAS-Luc Cell Lines Products
Signosis has developed the GAL4-UAS-Luc Reporter Stable Cell Lines as a reliable, rapid, and sensitive method for analyzing the expression of your target gene of interest upon exposure to related ligands or other stimuli. These cell lines are transfected only with the GAL4-UAS-LUC vector, and are ready to be transfected with your customized GAL4 vector containing your NR of interest.
Name | SKU | Formatted Price |
|---|---|---|
UAS Luciferase Reporter CHO Stable Cell Line | SL-5000 | $2,000.00 |
UAS Luciferase Reporter HEK293 Stable Cell Line | SL-3000 | $2,000.00 |
UAS Luciferase Reporter HeLa Stable Cell Line | SL-4000 | $2,000.00 |
Benefits
Isoform-Specific Detection
Designed to measure the activity of individual NHR isoforms, avoiding cross-reactivity seen in traditional assays.
Consistent and Reliable
Stably integrated reporter constructs ensure reproducible performance without the need for repeated transfections.
Validated and Ready to Use
Each cell line is tested for correct receptor expression, ligand response, and antibiotic selection.
Improved Accuracy
Focuses on the receptor’s ligand-binding domain (LBD), not the shared DNA-binding region, for more precise results.
Fast and Easy Screening
Ideal for testing drugs or compounds that target nuclear receptors like PPARα, PPARγ, GRα, and others.
We offer a highly sensitive Firefly Luciferase Substrate, which can accurately measure firefly luciferase activity in cells.
Ligand-Responsive Readout
Uses the GAL4-UAS luciferase system to give a strong, measurable signal only when a ligand activates the receptor.
Mechanism-Focused Research
Helps researchers better understand how specific NHR isoforms function in different pathways or diseases.
Mycoplasma Free
All cell lines have been tested negative for mycoplasma.
Research Application
-
Studying the effects of ligand binding on GAL4-mediated transcriptional activity
-
Identifying ligands that activate or inhibit the target receptors by monitoring GAL4-driven luciferase expression
-
Screening for potential therapeutic compounds that modulate the target receptors by measuring changes in luciferase activity
-
Investigating the mechanisms underlying the regulation of the target receptors by analyzing the GAL4-mediated transcriptional response to various stimuli
-
Comparing the activity and selectivity of different compounds on the target receptors by using the GAL4 reporter assay
-
Studying the interaction between the target receptors and other signaling pathways or co-regulators by analyzing the changes in GAL4-mediated transcriptional activity upon co-expression of different genes or treatments.
